VIRGINIA RETIREMENT SYSTEMS ET Al Takes Position in ANI Pharmaceuticals, Inc. $ANIP

VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in the 2nd quarter, Holdings Channel.com reports. The firm bought 17,500 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,449,000.

A number of other hedge funds have also recently bought and sold shares of the company. Penn Capital Management Company LLC lifted its holdings in ANI Pharmaceuticals by 2,058.9% in the 4th quarter. Penn Capital Management Company LLC now owns 137,394 shares of the specialty pharmaceutical company’s stock valued at $10,858,000 after acquiring an additional 131,030 shares during the last quarter. CenterBook Partners LP bought a new stake in shares of ANI Pharmaceuticals in the 4th quarter worth approximately $1,518,000. Jupiter Topco LLC bought a new stake in shares of ANI Pharmaceuticals in the 2nd quarter worth approximately $6,597,000. NFJ Investment Group LLC acquired a new stake in ANI Pharmaceuticals during the second quarter valued at approximately $2,766,000. Finally, Walleye Capital LLC acquired a new stake in ANI Pharmaceuticals during the second quarter valued at approximately $8,784,000. 76.05% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other ANI Pharmaceuticals news, SVP Ori Gutwerg sold 3,162 shares of ANI Pharmaceuticals stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $77.00, for a total transaction of $243,474.00. Following the transaction, the senior vice president directly owned 75,534 shares in the company, valued at approximately $5,816,118. The trade was a 4.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Nikhil Lalwani sold 5,400 shares of the business’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $74.30, for a total transaction of $401,220.00. Following the sale, the chief executive officer directly owned 344,489 shares in the company, valued at approximately $25,595,532.70. This trade represents a 1.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 21,425 shares of company stock worth $1,687,370 in the last quarter. Insiders own 8.10% of the company’s stock.

ANI Pharmaceuticals Price Performance

NASDAQ ANIP opened at $70.19 on Friday. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99. ANI Pharmaceuticals, Inc. has a 1 year low of $69.58 and a 1 year high of $99.39. The company has a market cap of $1.61 billion, a PE ratio of 15.13 and a beta of 0.45. The stock’s 50-day moving average price is $77.26 and its two-hundred day moving average price is $78.19.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, topping the consensus estimate of $2.04 by $0.17. The company had revenue of $266.04 million during the quarter, compared to analysts’ expectations of $260.13 million. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The business’s revenue for the quarter was up 25.8% on a year-over-year basis. During the same period last year, the company posted $1.80 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, analysts predict that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on ANIP. Canaccord Genuity Group reduced their target price on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a report on Monday, August 10th. Guggenheim dropped their price target on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a report on Monday, August 10th. Weiss Ratings downgraded ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Wall Street Zen lowered ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Finally, Leerink Partners initiated coverage on ANI Pharmaceuticals in a report on Wednesday. They issued an “outperform” rating and a $104.00 target price on the stock. Five equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $105.57.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with complex formulations, manufacturing requirements or specialized commercial opportunities, and serves a range of therapeutic areas.

ANI’s portfolio includes Cortrophin-Zinc, a repository corticotropin injection used for certain autoimmune and inflammatory conditions, along with a selection of branded and generic medicines.